Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses

Gut

Volumn 49, Issue 6, 2001, Pages 783-789

  Kruis, W ^a   Schreiber, S ^b   Theuer, D ^c   Brandes, J W ^d   Schtutz E ^e   Howaldt, S ^f   Krakamp, B ^g   Hamling J ^h   Monnikes H ⁱ   Koop, I ^j   Stolte, M ^k   Pallant, D ^l   Ewald, U ^m  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c Gastroenterologische Praxis   (Germany)

^d KLINIKUM BRAUNSCHWEIG   (Germany)

^e Castra Regina Center   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

^g KRANKENHAUS MERHEIM   (Germany)

^h Krankenhaus Tabea   (Germany)

ⁱ PHILIPPS UNIVERSITY MARBURG   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k Pathologisches Institut   (Germany)

^l ASTRAZENECA R AND D   (Sweden)

^m Astra Zeneca GmbH   (Germany)

more..

Author keywords

Aminosalicylic acid; Balsalazide; Mesalazine; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; BALSALAZIDE; EUDRAGIT; MESALAZINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS;

AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; COLON; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MESALAMINE; PHENYLHYDRAZINES; PRODRUGS;

EID: 0035181627     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.49.6.783     Document Type: Article

References (19)

1. The treatment of ulcerative colitis with balsalazide sodium
2. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis
3. Randomized comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis
4. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
5. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomized study
6. Biopsy studies in ulcerative colitis
7. Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine
8. Rapid differentiation of glomerular and tubular proteinuria by SDS-polyacrylamide gel electrophoresis
9. Ultra thin layer sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining of urinary proteins
10. Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis
11. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day
12. Short report: Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months
13. Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months
14. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis: A randomized double-blind multicentre trial
15. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis
16. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis
17. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylates
18. Renal and urologic complications of inflammatory bowel disease
19. Olsalazine is associated with lower systemic exposure to 5-ASA than mesalazine: A metaanalysis of five independent studies